급성 백혈병 환자를 위한 감정 및 증상 중심 참여 시험 (EASE)
감정 및 증상 중심 참여(EASE): 급성 백혈병 환자를 위한 개입의 다중 사이트 무작위 통제 시험
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.
Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).
A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Harriet Richardson
- 전화번호: 613-533-6430
- 이메일: hrichardson@ctg.queensu.ca
연구 연락처 백업
- 이름: Lois Shepherd
- 전화번호: 613-533-6430
- 이메일: lshepherd@ctg.queensu.ca
연구 장소
-
-
New Brunswick
-
Saint John, New Brunswick, 캐나다, E2L 4L2
- 모병
- Regional Health Authority B, Zone 2
-
연락하다:
- Alfonso Rivera Duarte
- 전화번호: 506 648-7109
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8V 5C2
- 모병
- Juravinski Cancer Centre at Hamilton Health Sciences
-
연락하다:
- Alejandro Garcia-Horton
-
Kingston, Ontario, 캐나다, K7L 2V7
- 모병
- Kingston Health Sciences Centre
-
연락하다:
- Annette Hay
- 전화번호: 77094 613 533-6430
-
Ottawa, Ontario, 캐나다, K1H 8L6
- 모병
- Ottawa Hospital Research Institute
-
연락하다:
- Pierre Villeneuve
- 전화번호: 613
-
Toronto, Ontario, 캐나다, M5G 2M9
- 모병
- University Health Network
-
연락하다:
- Gary Rodin
- 전화번호: 416 946-4504
-
Toronto, Ontario, 캐나다, M4N 3M5
- 모병
- Odette Cancer Centre
-
연락하다:
- Lee Mozessohn
- 전화번호: 5847 416 480-5000
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
- Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
- Age ≥ 18 years.
- Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
- Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.
Exclusion Criteria:
- Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
- Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
- Receiving on-site (in hospital) palliative care services at the time of recruitment.
- A diagnosis of acute promyelocytic leukemia.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 기타: 평소 관리
|
The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial |
|
실험적: Behavioral: Usual Care + EASE Intervention-psy
EASE Intervention = EASE-psy + EASE-phys |
All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT). -EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
기간: 4 weeks
|
This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome |
4 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
SASRQ를 사용하여 외상성 스트레스 증상을 줄이기 위한 일반적인 치료와 비교하여 EASE 개입의 효과를 평가합니다.
기간: 8주, 12주, 26주
|
8주, 12주, 26주
|
|
|
MSAS를 사용하여 신체적 증상의 중증도를 줄이기 위해 일반적인 치료에 대한 EASE 개입의 효과를 평가합니다.
기간: 8주, 12주, 26주
|
8주, 12주, 26주
|
|
|
SASRQ를 사용하여 DSM-5 기준에 따라 ASD 진단 및 역치 ASD와 일치하는 기준을 충족하는 참가자 수에 대한 일반적인 치료와 비교하여 EASE 개입의 효과를 평가합니다.
기간: 4주, 8주, 12주 및 26주
|
4주, 8주, 12주 및 26주
|
|
|
(MSAS)에 의해 측정된 암의 신체적 증상 및 관련 증상 관련 고통의 수에 대한 일반적인 치료와 비교하여 EASE 개입의 효과를 평가합니다.
기간: 4주, 8주, 12주, 26주
|
4주, 8주, 12주, 26주
|
|
|
16개 항목 FAMCAR-P16을 사용하여 치료에 대한 환자 만족도에 대한 일반적인 치료와 비교하여 EASE 개입의 효과를 평가합니다.
기간: 4주, 8주, 12주 및 26주
|
4주, 8주, 12주 및 26주
|
|
|
10) EQ-5D-5L은 일반 건강 상태를 측정하는 데 사용되어 EASE 개입의 이점과 비용을 비교하는 경제적 평가에서 품질 조정 수명(QALY)을 계산하는 데 사용할 수 있습니다.
기간: 4주, 8주, 12주, 26주 및 52주
|
4주, 8주, 12주, 26주 및 52주
|
|
|
치료군 간의 무진행 생존 기간을 비교하기 위해
기간: 일년
|
일년
|
|
|
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
기간: 4 weeks
|
This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome |
4 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
기간: 4, 8, 12, 26 and 52 weeks
|
Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being |
4, 8, 12, 26 and 52 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
기간: 4, 8 ,12 and 26 weeks
|
This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis. |
4, 8 ,12 and 26 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
기간: 4, 8 12 and 26 weeks
|
The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes |
4, 8 12 and 26 weeks
|
|
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
기간: Baseline
|
It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study. |
Baseline
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 의자: Gary Rodin, Princess Margaret Hospital, Canada
- 연구 의자: Camilla Zimmerman, Princess Margaret Hospital, Canada
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- SC26
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .